PDF(Pubmed)
Abstract：
UNASSIGNED: No reports on Letrozole as a pretreatment before ablation of uterine fibroid with high intensity focused ultrasound (HIFU), so a retrospective observation study was performed to evaluate the response of different pre-HIFU medication.
UNASSIGNED: We collected patients with single uterine fibroid receiving HIFU ablation from January 2018 to April 2021. All enrolled patients were classified into three group: group A (no pre-HIFU medication use), group B (Pre-HIFU letrozole use), group C (pre-HIFU gonadotrophin releasing hormone analog, GnRHa). Further associated clinical data and treatment response after HIFU treatment were reviewed and evaluated.
UNASSIGNED: A total of 39 patients including 21, 7, and 11 in group A, B, and C were collected respectively. After pre-HIFU medication, no difference of fibroid volume was found (A: 251.4, B: 360.6, C: 409.4 cm3, p = 0.250), and GnRHa group had significantly larger volume reduction than Letrozole users (38.6% vs. 16.4%, p = 0.007). The incidence of hypoestrogenic symptoms was higher in GnRHa group than in letrozole users (27.3% vs. 0, p = 0.170). GnRHa group had more sonication time (p = 0.001), treatment duration (p = 0.002), and ablated energy (p = 0.001) than group A and B. The treatment efficiency was higher in letrozole group than that in other 2 groups (4.52 vs. 2.39 vs. 2.34 cm3/min, p = 0.050). For patients with fibroid over 10 cm in diameter, letrozole group had even better energy efficiency (p = 0.067), treatment speed (p = 0.007), treatment efficiency (p = 0.001), NPV per energy (p = 0.005), and NPV per sonication (p = 0.004) than other 2 groups.
UNASSIGNED: Letrozole as a pretreatment medication before HIFU treatment might increase the energy efficiency and treatment efficiency of its ablation of uterine leiomyoma, especially for fibroid over 10 cm. Future study of larger patient number is needed to confirm our results.
UNASSIGNED: We collected patients with single uterine fibroid receiving HIFU ablation from January 2018 to April 2021. All enrolled patients were classified into three group: group A (no pre-HIFU medication use), group B (Pre-HIFU letrozole use), group C (pre-HIFU gonadotrophin releasing hormone analog, GnRHa). Further associated clinical data and treatment response after HIFU treatment were reviewed and evaluated.
UNASSIGNED: A total of 39 patients including 21, 7, and 11 in group A, B, and C were collected respectively. After pre-HIFU medication, no difference of fibroid volume was found (A: 251.4, B: 360.6, C: 409.4 cm3, p = 0.250), and GnRHa group had significantly larger volume reduction than Letrozole users (38.6% vs. 16.4%, p = 0.007). The incidence of hypoestrogenic symptoms was higher in GnRHa group than in letrozole users (27.3% vs. 0, p = 0.170). GnRHa group had more sonication time (p = 0.001), treatment duration (p = 0.002), and ablated energy (p = 0.001) than group A and B. The treatment efficiency was higher in letrozole group than that in other 2 groups (4.52 vs. 2.39 vs. 2.34 cm3/min, p = 0.050). For patients with fibroid over 10 cm in diameter, letrozole group had even better energy efficiency (p = 0.067), treatment speed (p = 0.007), treatment efficiency (p = 0.001), NPV per energy (p = 0.005), and NPV per sonication (p = 0.004) than other 2 groups.
UNASSIGNED: Letrozole as a pretreatment medication before HIFU treatment might increase the energy efficiency and treatment efficiency of its ablation of uterine leiomyoma, especially for fibroid over 10 cm. Future study of larger patient number is needed to confirm our results.
摘要：
未经证实：没有关于来曲唑作为高强度聚焦超声（HIFU）消融子宫肌瘤前预处理的报道，因此,我们进行了一项回顾性观察研究,以评估HIFU前不同药物的反应.
UNASSIGNED：我们收集了2018年1月至2021年4月接受HIFU消融的单发子宫肌瘤患者。所有入选患者分为三组：A组（未使用HIFU前药物），B组（HIFU前使用来曲唑），C组(HIFU前促性腺激素释放激素类似物，GnRHa).回顾并评估HIFU治疗后的进一步相关临床数据和治疗反应。
未经批准：共39例患者，其中A组21、7、11例，B,分别收集C。在HIFU前用药后，肌瘤体积无差异(A:251.4,B:360.6,C:409.4cm3,p=0.250),GnRHa组的体积减少量明显大于来曲唑用户(38.6%vs.16.4%,p=0.007)。GnRHa组的低雌激素症状发生率高于来曲唑使用者（27.3%vs.0,p=0.170)。GnRHa组的超声处理时间更长（p=0.001），治疗持续时间（p=0.002），和消融能量（p=0.001）高于A组和B组。来曲唑组的治疗效率高于其他2组（4.52vs.2.39vs.2.34cm3/min,p=0.050)。对于直径超过10厘米的肌瘤患者，来曲唑组具有更好的能量效率（p=0.067），治疗速度（p=0.007），治疗效率（p=0.001），每能源净现值(p=0.005)，每次超声处理的NPV（p=0.004）高于其他两组。
UNASSIGNED：来曲唑作为HIFU治疗前的预处理药物可能会增加其消融子宫平滑肌瘤的能量效率和治疗效率，特别是对于超过10厘米的纤维瘤。未来需要对更多患者进行研究以证实我们的结果。
UNASSIGNED：我们收集了2018年1月至2021年4月接受HIFU消融的单发子宫肌瘤患者。所有入选患者分为三组：A组（未使用HIFU前药物），B组（HIFU前使用来曲唑），C组(HIFU前促性腺激素释放激素类似物，GnRHa).回顾并评估HIFU治疗后的进一步相关临床数据和治疗反应。
未经批准：共39例患者，其中A组21、7、11例，B,分别收集C。在HIFU前用药后，肌瘤体积无差异(A:251.4,B:360.6,C:409.4cm3,p=0.250),GnRHa组的体积减少量明显大于来曲唑用户(38.6%vs.16.4%,p=0.007)。GnRHa组的低雌激素症状发生率高于来曲唑使用者（27.3%vs.0,p=0.170)。GnRHa组的超声处理时间更长（p=0.001），治疗持续时间（p=0.002），和消融能量（p=0.001）高于A组和B组。来曲唑组的治疗效率高于其他2组（4.52vs.2.39vs.2.34cm3/min,p=0.050)。对于直径超过10厘米的肌瘤患者，来曲唑组具有更好的能量效率（p=0.067），治疗速度（p=0.007），治疗效率（p=0.001），每能源净现值(p=0.005)，每次超声处理的NPV（p=0.004）高于其他两组。
UNASSIGNED：来曲唑作为HIFU治疗前的预处理药物可能会增加其消融子宫平滑肌瘤的能量效率和治疗效率，特别是对于超过10厘米的纤维瘤。未来需要对更多患者进行研究以证实我们的结果。
